Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Apple Turns 50: From Garage Startup to AI Crossroads 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
EMERYVILLE, Calif., Sept. 20, 2016 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, will present a corporate update at the Ladenburg Thalmann 2016 Healthcare Conference, and will participate in a fireside chat at the LEERINK Partners Rare Disease & Immuno-Oncology Roundtable Series.
Ladenburg Thalmann 2016 Healthcare Conference -- Zogenix Presentation Details
| Date: | Tuesday, September 27, 2016 | |||
| Time: | 4:00 pm Eastern Time / 1:00 pm Pacific Time | |||
| Location: | New York, NY | |||
LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology -- Zogenix Presentation Details
| Date: | Wednesday, September 28, 2016 | |||||
| Time: | 10:00 am Eastern Time / 7:00 am Pacific Time | |||||
| Location: | New York, NY | |||||
The presentations will be webcast live and can be accessed on Zogenix's Investor Relations website at ir.zogenix.com.
About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT: Investors: Andrew McDonald Founding Partner, LifeSci Advisors LLC 646-597-6987 | [email protected]
